Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Exome Sequencing Identified Pathogenic Variants in Cerebral Palsy Patients

By LabMedica International staff writers
Posted on 18 Feb 2021
Cerebral palsy (CP) is a group of permanent movement disorders that appear in early childhood. More...
Signs and symptoms vary among people and over time. Often, symptoms include poor coordination, stiff muscles, weak muscles, and tremors.

Cerebral palsy is caused by abnormal development or damage to the parts of the brain that control movement, balance, and posture. Most often, the problems occur during pregnancy; however, they may also occur during childbirth or shortly after birth. While CP has often been attributed to oxygen deprivation during birth, recent studies have suggested that birth asphyxia accounts for less than 10% of cerebral palsy cases and that genetic variants affect disease risk.

Medical Scientists at the Geisinger Medical Center (Danville, PA, USA) and their colleagues carried out a retrospective, cross-sectional cohort study of cerebral palsy. One cohort consisted of 1,345 individuals with cerebral palsy had a median age of 8.8 years old and underwent exome sequencing at GeneDx (Gaithersburg, MD, USA). The other cohort, meanwhile, included 181 individuals with cerebral palsy who were a median age of 41.9 years old and who were recruited from the DiscoverEHR project from Geisinger and the Regeneron Genetics Center. This second cohort underwent research-based exome sequencing.

The team reported that for the younger cohort exome sequencing led to a positive diagnostic result for 440 patients, or 32.7%. Trio testing, the test subject and both biological parents, was available for a subset of that cohort, which boosted diagnostic yield from 23.3% for the affected individuals only to 35.4% in trio testing. Meanwhile, exome sequencing led to a positive diagnostic result for 19 patients, or 10.5%, from the second, older cohort.

Additionally, the scientists identified genes that harbored alterations in two or more unrelated individuals with cerebral palsy, including CTNNB1, KIF1A, GNAO1, and TUBA1A. Mutations in CTNNB1, they noted, have previously been reported in individuals with cerebral palsy and an autosomal dominant neurodevelopmental disorder marked by intellectual disability, spasticity, microcephaly, and visual defects. Pathogenic and likely pathogenic variants were identified in 229 genes (29.5% of 1,526 patients); 86 genes were mutated in two or more patients (20.1% of 1526 patients) and 10 genes with mutations were independently identified in both cohorts (2.9% of 1526 patients).

Andrés Moreno De Luca, a Neuroradiologist and assistant professor and first author of the study, said, “Finding a genetic etiology has the potential to prompt changes in clinical management, provide an end to the diagnostic odyssey and important prognostic information for patients and families, inform recurrence risk for future children born to the same parents, and may have medicolegal implications in cases of alleged birth asphyxia.”

The authors concluded that among two cohorts of patients with cerebral palsy who underwent exome sequencing, the prevalence of pathogenic and likely pathogenic variants was 32.7% in a cohort that predominantly consisted of pediatric patients and 10.5% in a cohort that predominantly consisted of adult patients. The study was published on February 2, 2021 in the Journal of the American Medical Association.

Related Links:
Geisinger Medical Center
GeneDx



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.